{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T19:27:55Z","timestamp":1791660475303,"version":"4.3.4"},"reference-count":88,"publisher":"Japan Atherosclerosis Society","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT"],"published-print":{"date-parts":[[2012]]},"DOI":"10.5551\/jat.14621","type":"journal-article","created":{"date-parts":[[2012,10,24]],"date-time":"2012-10-24T22:43:02Z","timestamp":1351118582000},"page":"1043-1060","source":"Crossref","is-referenced-by-count":156,"title":["Guidelines for the Management of Familial Hypercholesterolemia"],"prefix":"10.5551","volume":"19","author":[{"given":"Mariko","family":"Harada-Shiba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Oikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoo","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Nohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Bujo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koutaro","family":"Yokote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Wakatsuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Ishibashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shizuya","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Mabuchi H, Koizumi J, Shimizu M, Takeda R: Development of coronary heart disease in familial hypercholesterolemia. Circulation, 1989; 79: 225-232","DOI":"10.1161\/01.CIR.79.2.225"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Rees A: Familial hypercholesterolaemia: underdiagnosed and undertreated. Eur Heart J, 2008; 29: 2583-2584","DOI":"10.1093\/eurheartj\/ehn448"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Teramoto T: Status of lipid-lowering therapy prescribed on recommendations in the 2002 report of the Japan Atherosclerosis Society Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese Adults: A study of the Japan Lipid Assessment Program (J-LAP). Curr Ther Res, 2005; 66: 80-95","DOI":"10.1016\/j.curtheres.2005.04.004"},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2005.04.004"},{"key":"5","doi-asserted-by":"crossref","unstructured":"4) Mabuchi H: Introduction to Hyperlipidemia. Edited by Asai H, pp35-61, Bunkodo, Tokyo, 2005","DOI":"10.1385\/1-59259-881-1:061"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.5551\/jat.11.146"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2004.10.011"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(02)00249-6"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2010.11.005"},{"key":"10","unstructured":"9) Ohta N, Yoshida H, Teramoto T, Oikawa S, Saito Y, Yamada N, Shirai K, Ishibashi S, Ishikawa T, Yoshino G, Hirano T: Survey regarding hyperlipidemia treatment in Japan (Survey 1: Complications in hyper-LDL-cholesterolemia and familial hypercholesterolemia patients, as well as survey regarding selected drugs)-LiMAP1-. 37th meeting held by the Japan Atherosclerosis Society, 2005;"},{"key":"11","unstructured":"9) Ohta N, Yoshida H, Teramoto T, Oikawa S, Saito Y, Yamada N, Shirai K, Ishibashi S, Ishikawa T, Yoshino G, Hirano T: Survey regarding hyperlipidemia treatment in Japan (Survey 1: Complications in hyper-LDL-cholesterolemia and familial hypercholesterolemia patients, as well as survey regarding selected drugs)-LiMAP1-. 37th meeting held by the Japan Atherosclerosis Society, 2005;"},{"key":"12","doi-asserted-by":"publisher","DOI":"10.5551\/jat.11.131"},{"key":"13","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2009.11.018"},{"key":"14","doi-asserted-by":"publisher","DOI":"10.5551\/jat.12.35"},{"key":"15","doi-asserted-by":"crossref","unstructured":"13) Yagi K, Hifumi S, Nohara A, Higashikata T, Inazu A, Mizuno KO, Namura M, Ueda K, Kobayashi J, Shimizu M, Mabuchi H: Difference in the risk factors for coronary, renal and other peripheral arteriosclerosis in heterozygous familial hypercholesterolemia. Circ J, 2004; 68: 623-627","DOI":"10.1253\/circj.68.623"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.5551\/jat.11536"},{"key":"17","doi-asserted-by":"crossref","unstructured":"15) Hirobe K, Matsuzawa Y, Ishikawa K, Tarui S, Yamamoto A, Nambu S, Fujimoto K: Coronary artery disease in heterozygous familial hypercholesterolemia. Atherosclerosis, 1982; 44: 201-210","DOI":"10.1016\/0021-9150(82)90114-9"},{"key":"18","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(97)00076-2"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0800445"},{"key":"20","unstructured":"18) Report in 1986 published by the Specific Disease Primary Hyperlipidemia Survey Research Group, Ministry of Health, Labour and Welfare"},{"key":"21","doi-asserted-by":"crossref","unstructured":"19) Rana JS, Jansen AC, Zwinderman AH, Nieuwdorp M, van Aalst-Cohen ES, Jukema JW, Trip MD, Kastelein JJ: Metabolic syndrome and risk of coronary, cerebral, and peripheral vascular disease in a large Dutch population with familial hypercholesterolemia. Diabetes Care, 2006, 29: 1125-1127","DOI":"10.2337\/dc05-2530"},{"key":"22","doi-asserted-by":"crossref","unstructured":"20) Jansen AC, van Aalst-Cohen ES, Tanck MW, Trip MD, Lansberg PJ, Liem AH, van Lennep HW, Sijbrands EJ, Kastelein JJ: The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med, 2004; 256: 482-490","DOI":"10.1111\/j.1365-2796.2004.01405.x"},{"key":"23","doi-asserted-by":"crossref","unstructured":"21) Jensen HK, Hansen PS, Jensen LG, Kristensen MJ, Klausen IC, Kjeldsen M, Lemming L, Bolund L, Gregersen N, Faergeman O: Complexity of molecular genetics of dyslipidemia in a family highly susceptible to ischemic heart disease. Clinical genetics, 1995; 48: 23-28","DOI":"10.1111\/j.1399-0004.1995.tb04049.x"},{"key":"24","doi-asserted-by":"crossref","unstructured":"22) Holmes DT, Schick BA, Humphries KH, Frohlich J: Lipoprotein(a) is an independent risk factor for cardiovascular disease in heterozygous familial hypercholesterolemia. Clin Chem, 2005; 51: 2067-2073","DOI":"10.1373\/clinchem.2005.055228"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2011.02.007"},{"key":"26","doi-asserted-by":"crossref","unstructured":"24) van Wissen S, Smilde TJ, de Groot E, Hutten BA, Kastelein JJ, Stalenhoef AF: The significance of femoral intima-media thickness and plaque scoring in the Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) study. European journal of cardiovascular prevention and rehabilitation, 2003; 10: 451-455","DOI":"10.1097\/01.hjr.0000103277.02552.1e"},{"key":"27","doi-asserted-by":"publisher","DOI":"10.5551\/jat.4143"},{"key":"28","doi-asserted-by":"crossref","unstructured":"26) Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA, Gaudet D, Duivenvoorden R, Veltri EP, Marais AD, de Groot E: Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med, 2008; 358: 1431-1443","DOI":"10.1056\/NEJMoa0800742"},{"key":"29","doi-asserted-by":"publisher","DOI":"10.5551\/jat.E610"},{"key":"30","doi-asserted-by":"crossref","unstructured":"28) van der Graaf A, Cuffie-Jackson C, Vissers MN, Trip MD, Gagne C, Shi G, Veltri E, Avis HJ, Kastelein JJ: Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol, 2008; 52: 1421-1429","DOI":"10.1016\/j.jacc.2008.09.002"},{"key":"31","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.17.2271"},{"key":"32","doi-asserted-by":"crossref","unstructured":"30) Natural history of aortic and coronary atherosclerotic lesions in youth. Findings from the PDAY Study. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arterioscler Thromb, 1993; 13: 1291-1298","DOI":"10.1161\/01.ATV.13.9.1291"},{"key":"33","doi-asserted-by":"publisher","DOI":"10.1046\/j.1442-200X.2002.01634.x"},{"key":"34","unstructured":"32) Hattori H NM, Kawamura K, Ishii J, Tsuji M, Iwata F, Yamamura T, Miyake Y, Egashira T, Okada T, Cooper JA, Miller NE, Emi M, Yamamoto A: A flow cytometric procedure to measure functional LDL receptors for diagnosis of familial hypercholesterolemia. Edited by pp357-363, MEDIMOND Inc, Salzburg, 2002"},{"key":"35","doi-asserted-by":"publisher","DOI":"10.1046\/j.1442-200X.2002.01635.x"},{"key":"36","doi-asserted-by":"crossref","unstructured":"34) Haney EM, Huffman LH, Bougatsos C, Freeman M, Steiner RD, Nelson HD: Screening and treatment for lipid disorders in children and adolescents: systematic evidence review for the US Preventive Services Task Force. Pediatrics, 2007; 120: e189-214","DOI":"10.1542\/peds.2006-1801"},{"key":"37","doi-asserted-by":"crossref","unstructured":"35) Kavey RE, Allada V, Daniels SR, Hayman LL, McCrindle BW, Newburger JW, Parekh RS, Steinberger J: Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation, 2006; 114: 2710-2738","DOI":"10.1161\/CIRCULATIONAHA.106.179568"},{"key":"38","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(95)00461-0"},{"key":"39","doi-asserted-by":"crossref","unstructured":"37) Davis PH, Dawson JD, Riley WA, Lauer RM: Carotid intimal-medial thickness is related to cardiovascular risk factors measured from childhood through middle age: The Muscatine Study. Circulation, 2001; 104: 2815-2819","DOI":"10.1161\/hc4601.099486"},{"key":"40","doi-asserted-by":"crossref","unstructured":"38) Klag MJ, Ford DE, Mead LA, He J, Whelton PK, Liang KY, Levine DM: Serum cholesterol in young men and subsequent cardiovascular disease. N Engl J Med, 1993; 328: 313-318","DOI":"10.1056\/NEJM199302043280504"},{"key":"41","doi-asserted-by":"crossref","unstructured":"38) Klag MJ, Ford DE, Mead LA, He J, Whelton PK, Liang KY, Levine DM: Serum cholesterol in young men and subsequent cardiovascular disease. N Engl J Med, 1993; 328: 313-318","DOI":"10.1056\/NEJM199302043280504"},{"key":"42","doi-asserted-by":"crossref","unstructured":"39) National Cholesterol Education Program (NCEP): highlights of the report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics, 1992; 89: 495-501","DOI":"10.1542\/peds.89.3.495"},{"key":"43","doi-asserted-by":"crossref","unstructured":"40) Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics, 2011; 128 Suppl 5: S213-256","DOI":"10.1542\/peds.2009-2107C"},{"key":"44","doi-asserted-by":"crossref","unstructured":"41) Rask-Nissila L, Jokinen E, Ronnemaa T, Viikari J, Tammi A, Niinikoski H, Seppanen R, Tuominen J, Simell O: Prospective, randomized, infancy-onset trial of the effects of a low-saturated-fat, low-cholesterol diet on serum lipids and lipoproteins before school age: The Special Turku Coronary Risk Factor Intervention Project (STRIP). Circulation, 2000; 102: 1477-1483","DOI":"10.1161\/01.CIR.102.13.1477"},{"key":"45","doi-asserted-by":"publisher","DOI":"10.1001\/jama.273.18.1429"},{"key":"46","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)02593-7"},{"key":"47","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.3.331"},{"key":"48","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.2.137"},{"key":"49","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000035247.42888.82"},{"key":"50","doi-asserted-by":"crossref","unstructured":"47) Avis HJ, Hutten BA, Gagne C, Langslet G, McCrindle BW, Wiegman A, Hsia J, Kastelein JJ, Stein EA: Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J Am Coll Cardiol, 2010; 55: 1121-1126","DOI":"10.1016\/j.jacc.2009.10.042"},{"key":"51","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2003.11.010"},{"key":"52","doi-asserted-by":"crossref","unstructured":"49) Khader YS, Rice J, John L, Abueita O: Oral contraceptives use and the risk of myocardial infarction: a metaanalysis. Contraception, 2003; 68: 11-17","DOI":"10.1016\/S0010-7824(03)00073-8"},{"key":"53","doi-asserted-by":"crossref","unstructured":"50) Simonson SG, Martin PD, Warwick MJ, Mitchell PD, Schneck DW: The effect of rosuvastatin on oestrogen & progestin pharmacokinetics in healthy women taking an oral contraceptive. Br J Clin Pharmacol, 2004; 57: 279-286","DOI":"10.1046\/j.1365-2125.2003.02015.x"},{"key":"54","doi-asserted-by":"crossref","unstructured":"51) Wakatsuki A, Sagara Y: Lipoprotein metabolism in postmenopausal and oophorectomized women. Obstet Gynecol, 1995; 85: 523-528","DOI":"10.1016\/0029-7844(94)00452-J"},{"key":"55","doi-asserted-by":"publisher","DOI":"10.1001\/jama.273.3.199"},{"key":"56","doi-asserted-by":"crossref","unstructured":"53) Wakatsuki A, Okatani Y, Ikenoue N: Effects of combination therapy with estrogen plus simvastatin on lipoprotein metabolism in postmenopausal women with type IIa hypercholesterolemia. Atherosclerosis, 2000; 150: 103-111","DOI":"10.1016\/S0021-9150(99)00350-0"},{"key":"57","doi-asserted-by":"crossref","unstructured":"54) Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH: Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses’ health study. N Engl J Med, 1991; 325: 756-762","DOI":"10.1056\/NEJM199109123251102"},{"key":"58","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.7.605"},{"key":"59","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.3.321"},{"key":"60","doi-asserted-by":"crossref","unstructured":"57) Lokkegaard E, Andreasen AH, Jacobsen RK, Nielsen LH, Agger C, Lidegaard O: Hormone therapy and risk of myocardial infarction: a national register study. Eur Heart J, 2008; 29: 2660-2668","DOI":"10.1093\/eurheartj\/ehn408"},{"key":"61","doi-asserted-by":"publisher","DOI":"10.1172\/JCI108980"},{"key":"62","doi-asserted-by":"publisher","DOI":"10.1038\/ng1161"},{"key":"63","doi-asserted-by":"publisher","DOI":"10.1038\/ng1509"},{"key":"64","doi-asserted-by":"crossref","unstructured":"61) Harada-Shiba M, Tajima S, Yokoyama S, Miyake Y, Kojima S, Tsushima M, Kawakami M, Yamamoto A: Siblings with normal LDL receptor activity and severe hypercholesterolemia. Arteriosclerosis and thrombosis, 1992; 12: 1071-1078","DOI":"10.1161\/01.ATV.12.9.1071"},{"key":"65","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-021487"},{"key":"66","doi-asserted-by":"crossref","unstructured":"63) Hubacek JA, Berge KE, Cohen JC, Hobbs HH: Mutations in ATP-cassette binding proteins G5 (ABCG5) and G8 (ABCG8) causing sitosterolemia. Human mutation, 2001; 18: 359-360","DOI":"10.1002\/humu.1206"},{"key":"67","doi-asserted-by":"publisher","DOI":"10.1172\/JCI107640"},{"key":"68","doi-asserted-by":"crossref","unstructured":"65) Berge KE, Tian H, Graf GA, Yu L, Grishin NV, Schultz J, Kwiterovich P, Shan B, Barnes R, Hobbs HH: Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science, 2000; 290: 1771-1775","DOI":"10.1126\/science.290.5497.1771"},{"key":"69","doi-asserted-by":"crossref","unstructured":"66) Kim KS, Kubota S, Kuriyama M, Fujiyama J, Bjorkhem I, Eggertsen G, Seyama Y: Identification of new mutations in sterol 27-hydroxylase gene in Japanese patients with cerebrotendinous xanthomatosis (CTX). J Lipid Res, 1994; 35: 1031-1039","DOI":"10.1016\/S0022-2275(20)40096-3"},{"key":"70","doi-asserted-by":"crossref","unstructured":"67) Morganroth J, Levy RI, McMahon AE, Gotto AM Jr: Pseudohomozygous type II hyperlipoproteinemia. J Pediatr, 1974; 85: 639-643","DOI":"10.1016\/S0022-3476(74)80506-8"},{"key":"71","doi-asserted-by":"crossref","unstructured":"68) Fujita M, Okamoto S, Shirai K, Saito Y, Yoshida S: Pseudohomozygous type II hyperlipoproteinemia. Dermatologica, 1991; 182: 94-97","DOI":"10.1159\/000247753"},{"key":"72","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(86)90434-0"},{"key":"73","doi-asserted-by":"crossref","unstructured":"70) Thorogood M, Seed M, De Mott K: Management of fertility in women with familial hypercholesterolaemia: summary of NICE guidance. BJOG, 2009; 116: 478-479","DOI":"10.1111\/j.1471-0528.2008.02084.x"},{"key":"74","doi-asserted-by":"crossref","unstructured":"71) Thompson GR: Recommendations for the use of LDL apheresis. Atherosclerosis, 2008; 198: 247-255","DOI":"10.1016\/j.atherosclerosis.2008.02.009"},{"key":"75","doi-asserted-by":"publisher","DOI":"10.1046\/j.1526-0968.2003.00073.x"},{"key":"76","doi-asserted-by":"crossref","unstructured":"73) Thompson GR, Lowenthal R, Myant NB: Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet, 1975; 1: 1208-1211","DOI":"10.1016\/S0140-6736(75)92193-5"},{"key":"77","doi-asserted-by":"crossref","unstructured":"74) Yokoyama S, Hayashi R, Satani M, Yamamoto A: Selective removal of low density lipoprotein by plasmapheresis in familial hypercholesterolemia. Arteriosclerosis, 1985; 5: 613-622","DOI":"10.1161\/01.ATV.5.6.613"},{"key":"78","doi-asserted-by":"crossref","unstructured":"75) Yamamoto A, Harada-Shiba M, Kawaguchi A, Tsushima M: Apheresis technology for prevention and regression of atherosclerosis. Ther Apher, 2001; 5: 221-225","DOI":"10.1046\/j.1526-0968.2001.00328.x"},{"key":"79","doi-asserted-by":"crossref","unstructured":"76) Mabuchi H, Michishita I, Sakai T, Sakai Y, Watanabe A, Wakasugi T, Takeda R: Treatment of homozygous patients with familial hypercholesterolemia by double-filtration plasmapheresis. Atherosclerosis, 1986; 61: 135-140","DOI":"10.1016\/0021-9150(86)90073-0"},{"key":"80","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(98)00692-4"},{"key":"81","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)92961-4"},{"key":"82","doi-asserted-by":"crossref","unstructured":"79) Kroon AA, Aengevaeren WR, van der Werf T, Uijen GJ, Reiber JH, Bruschke AV, Stalenhoef AF: LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation, 1996; 93: 1826-1835","DOI":"10.1161\/01.CIR.93.10.1826"},{"key":"83","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(96)00388-9"},{"key":"84","doi-asserted-by":"crossref","unstructured":"81) Amundsen AL, Khoury J, Iversen PO, Bergei C, Ose L, Tonstad S, Retterstol K: Marked changes in plasma lipids and lipoproteins during pregnancy in women with familial hypercholesterolemia. Atherosclerosis, 2006; 189: 451-457","DOI":"10.1016\/j.atherosclerosis.2006.01.002"},{"key":"85","doi-asserted-by":"crossref","unstructured":"82) Amundsen AL, Khoury J, Sandset PM, Seljeflot I, Ose L, Tonstad S, Henriksen T, Retterstol K, Iversen PO: Altered hemostatic balance and endothelial activation in pregnant women with familial hypercholesterolemia. Thromb Res, 2007; 120: 21-27","DOI":"10.1016\/j.thromres.2006.07.001"},{"key":"86","doi-asserted-by":"crossref","unstructured":"83) Beigel Y, Bar J, Cohen M, Hod M: Pregnancy outcome in familial homozygous hypercholesterolemic females treated with long-term plasma exchange. Acta Obstet Gynecol Scad, 1998; 77: 603-608","DOI":"10.1034\/j.1600-0412.1998.770605.x"},{"key":"87","doi-asserted-by":"publisher","DOI":"10.1097\/01.mol.0000137222.23784.2a"},{"key":"88","doi-asserted-by":"crossref","unstructured":"85) Klingel R, Gohlen B, Schwarting A, Himmelsbach F, Straube R: Differential indication of lipoprotein apheresis during pregnancy. Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2003; 7: 359-364","DOI":"10.1046\/j.1526-0968.2003.00066.x"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,1,30]],"date-time":"2022-01-30T14:17:41Z","timestamp":1643552261000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/19\/12\/19_14621\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":88,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.14621","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012]]}}}